Assay.Works offers a comprehensive range of functional assessment and mechanistic analysis technologies for drug discovery across various therapeutic areas.
Our capabilities include:
- Bioactivity measurement for membrane-bound receptors (GPCRs, RTKs) via signaling pathways and second messengers
- Transporter and ion channel activity assessment through metabolite/ion flux and electrophysiology
- Direct measurement of molecular interactions (protein-protein, protein-nucleic acid)
- Protein degradation assays
- Biochemical, biophysical, and coupled enzymatic assays
- Imaging-based live-cell phenotypic analyses
- AI-powered cell painting for comprehensive drug candidate profiling.
These assays can be scaled from small (10-100 compounds) to large (1000-1000000 compounds) screening campaigns, enabling quantitative assessment of disease-relevant readouts for potential drug candidates across different modalities. This diverse assay portfolio allows for both target-based and phenotypic approaches in drug discovery.
At Assay.Works our partners can benefit from an integrated High-throughput screening (HTS) platform which:
- Combines standardized reader devices with adaptable workstations
- Allows for various functional measurements
- Adjustable for different complexity and throughput needs
